Tekturna Hct
Product Images NDC 54868-6194

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Tekturna Hct (NDC 54868-6194). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Physicians Total Care, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Of 150 mg / 12.5 mg Package Label (Package Label 01)

Packaging label for Tekturna HCT 150/12.5 mg tablets distributed by Physicians Total Care, Inc. The label includes a lot number, expiration date, and a barcode. Manufactured by Novartis Pharma GmbH in Wehr, Germany.*

FDA Label Image

Image Of 300 mg / 12.5 mg Package Label (Package Label 02)

Packaging label for Tekturna HCT 300/12.5 mg tablets distributed by Physicians Total Care, Inc. The label includes the lot number 0000 and an expiration date of January 2060. Manufactured by Novartis Pharma GmbH, Germany. The NDC is 54868-6103-0.*

FDA Label Image

Image Of 300 mg/ 25 mg Package Label (Package Label 03)

Tekturna HCT 300 mg/25 mg tablets packaging label from Physicians Total Care, Inc. The label indicates 90 tablets per container with active ingredients aliskiren and hydrochlorothiazide. It includes dosing information, storage instructions, supplier contact details, and the lot number and expiration date.*

FDA Label Image

Figure 1: Probability Of Achieving Systolic Blood Pressure (sbp) <140 Mmhg (Tekturna Hct 01)

A line graph showing predicted percentage of patients versus baseline mean seated systolic blood pressure (MSSBP) in mmHg. The graph compares data for four groups labeled ALI300, HCT225, ALI300/HCT225, and Placebo, with MSSBP ranging from 140 to 180 mmHg and predicted percentages decreasing as MSSBP increases.*

FDA Label Image

Figure 2: Probability Of Achieving Systolic Blood Pressure (sbp) <130 Mmhg (Tekturna Hct 02)

A line graph depicting predicted percentage of patients (%) versus baseline MSSBP (mmHg). The graph compares four groups: ALJ300, HCTZ25, ALJ300+HCTZ25, and Placebo, illustrating their predicted patient response trends across a range of baseline MSSBP values from 140 to 180 mmHg.*

FDA Label Image

Figure 3: Probability Of Achieving Diastolic Blood Pressure (dbp) <90 Mmhg (Tekturna Hct 03)

A line graph showing the predicted percentage of patients versus baseline mean systolic diastolic blood pressure (MSDBP) in mmHg for different treatments including ALJ300, HCT225, ALJ300/HCT225 combination, and placebo. The graph depicts trends of patient response across a range of baseline blood pressures from 90 to 110 mmHg.*

FDA Label Image

Figure 4: Probability Of Achieving Diastolic Blood Pressure (dbp) <80 Mmhg (Tekturna Hct 04)

A line graph showing the predicted percentage of patients (%) on the y-axis versus baseline MSDBP (mmHg) on the x-axis. The graph compares multiple data series labeled AUJ000, HCT225, AUJ001-HCT225, and Placebo, illustrating trends in patient predictions across different baseline blood pressure values.*

FDA Label Image

Aliskiren Chemical Structure (Tekturna Hct 05)

Chemical structure of the active ingredient associated with Tekturna HCT. The diagram shows the molecular structure including various functional groups and bonds, typical of a chemical compound used in pharmaceutical formulations.*

FDA Label Image

Hydrochlorothiazide Chemical Structure (Tekturna Hct 06)

Chemical structure diagram of the active ingredient in Tekturna HCT, showing a chlorinated aromatic ring with attached sulfonamide and amide groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.